Table 1.
Prevalence of antibodies against SARS-CoV-21 in people living in France2 at the end of the first lockdown according to cumulative hospitalisation and death rates cumulated until the first week of May at départment level: the national EpiCov cohort, round 1—May 2020
| Total | ELISA-S+ ELISA-S ≥ 1.1 |
SN+ Neutralisation assay ≥ 40 |
ELISA-S+ or SN+ | ELISA-S+/i ELISA-S ≥ 0.7 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | N | %3 | 95% CI3 | N | %3 | 95% CI3 | N | %3 | 95% CI3 | N | %3 | 95% CI3 | |
| Mainland France | 12,114 | 785 | 4.5 | [3.9–5.0] | 656 | 4.1 | [3.6–4.7] | 892 | 5.5 | [4.8–6.1] | 1132 | 7.1 | [6.4–7.8] |
| Quintile of hospitalisation rate | |||||||||||||
| 1st quintile (lowest rate) | 1017 | 30 | 2.7 | [1.5–3.9] | 24 | 1.9 | [1.1–2.7] | 38 | 3.3 | [2.0–4.6] | 61 | 5.7 | [4.0–7.5] |
| 2nd quintile | 1228 | 43 | 2.9 | [1.9–3.8] | 37 | 2.4 | [1.5–3.2] | 60 | 3.9 | [2.8–5.0] | 77 | 5.1 | [3.8–6.3] |
| 3rd quintile | 1170 | 52 | 3.6 | [2.5–4.7] | 50 | 3.6 | [2.5–4.8] | 62 | 4.4 | [3.1–5.6] | 72 | 5.2 | [3.9–6.6] |
| 4st quintile | 3378 | 148 | 4.1 | [2.9–5.3] | 115 | 4.7 | [3.2–6.2] | 170 | 5.6 | [4.1–7.2] | 245 | 7.2 | [5.5–8.9] |
| 5st quintile (highest rate) | 5321 | 512 | 9.2 | [7.4–10.9] | 430 | 8.0 | [6.3–9.7] | 562 | 10.0 | [8.2–11.7] | 677 | 12.4 | [10.5–14.3] |
| Sextile of death rate | |||||||||||||
| 1st sextile (lowest rate) | 734 | 19 | 2.3 | [1.1–3.4] | 16 | 1.6 | [0.8–2.5] | 27 | 3.1 | [1.8–4.4] | 40 | 4.8 | [3.1–6.5] |
| 2nd sextile | 1156 | 26 | 2.7 | [1.6–3.8] | 31 | 2.3 | [1.4–3.1] | 47 | 3.6 | [2.4–4.8] | 67 | 5.4 | [3.8–6.9] |
| 3rd sextile | 892 | 38 | 3.6 | [2.3–4.9] | 35 | 3.2 | [2.0–4.4] | 49 | 4.4 | [3.0–5.8] | 62 | 5.9 | [4.2–7.5] |
| 4st sextile | 2393 | 99 | 3.4 | [2.5–4.4] | 71 | 3.8 | [2.5–5.1] | 113 | 4.7 | [3.3–6.1] | 165 | 5.8 | [4.3–7.3] |
| 5st sextile | 1780 | 91 | 5.3 | [3.5–7.1] | 84 | 5.7 | [3.7–7.6] | 106 | 6.4 | [4.4–8.5] | 134 | 7.7 | [5.5–9.9] |
| 6st sextile (highest rate) | 5159 | 502 | 9.5 | [7.6–11.3] | 419 | 8.1 | [6.3–9.9] | 550 | 10.3 | [8.4–12.2] | 664 | 12.9 | [10.9–15.0] |
Bold is used to underline % and OR
1Home sampling for finger prick/Euroimmun ELISA-S and seroneutralization tests
2People aged 15 or over, residing in mainland France, but not in care homes for the elderly or prisons
3The sampling design is taken into account for the estimation of prevalence, confidence intervals, with the SAS procsurvey procedure. The percentages are weighted by sampling weight (the inverse of inclusion probability), corrected for non-response probability and calibrated on the margin of the census. The prevalences are not equal to n/N